Patient characteristics
| Patient no. . | Age, y . | Sex, recipient/donor . | CP . | HS . | Donor . | BM/PB . | Conditioning . | GVHD prophylaxis . | Acute GVHD . | Chronic GVHD . | MRD status, last follow-up (mo) . | Follow-up, mo (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N1 | 63 | F/F | 1 | IR | SIB | PB | Flu/Bu/ATG | MMF/CsA/Pr | I | None | − (27) | 29 (R) |
| N2 | 50 | M/M | 1 | HR | SIB | PB | Flu/Bu/ATG | MTX/CsA | III | None | − (5) | 5 (D) |
| N3 | 53 | F/F | 1 | NA | SIB | PB | Flu/Bu/ATG | MTX/CsA | I | Lim | − (21) | 22 |
| N4 | 55 | F/F | 1 | IR | MUD | PB | Flu/Bu/ATG | MTX/CsA | None | Lim | − (20) | 21 |
| N5 | 62 | F/M | 1 | IR | SIB | PB | Flu/Bu/ATG | MTX/CsA | None | Lim | − (7) | 8.5 |
| N6 | 56 | F/M | 1 | IR | MUD | BM | Flu/Bu/ATG | MTX/CsA | I | None | + (7) | 8.5 |
| N7 | 56 | F/F | 1 | IR | SIB | BM | Flu/Bu/ATG | MTX/CsA | None | None | − (6) | 6 |
| N8 | 58 | F/F | 1 | HR | SIB | PB | Flu/Bu/ATG | CsA | II | Lim | + (29) | 31 |
| N9 | 40 | F/M | 1 | LR | SIB | PB | Flu/Bu/ATG | CsA | II | Ext | − (24) | 24 |
| N10 | 44 | M/M | 1 | LR | SIB | PB | Flu/Bu/ATG | CsA | II | Lim | − (18) | 21 |
| N11 | 50 | M/M | 1 | LR | SIB | PB | Flu/Bu/ATG | MTX/CsA | II | Lim | − (20) | 20 |
| N12 | 49 | M/M | 1 | HR | MUD | BM | Flu/Bu/ATG | MTX/CsA | II | Ext | + (17) | 17 (D) |
| N13 | 46 | F/M | 1 | LR | MUD | PB | Flu/Bu/ATG | MTX/CsA | I | None | − (13) | 14 |
| N14 | 36 | F/M | 1 | LR | MUD | PB | Flu/Bu/ATG | MTX/CsA | None | None | − (13) | 14 |
| N15 | 51 | M/F | 1 | HR | SIB | PB | Flu/Bu/ATG | MTX/CsA | II | Lim | + (8) | 8 |
| C1 | 35 | M/M | 1 | LR | MUD | BM | TBI/Cy/ATG | MTX/CsA | I | Ext | − (28) | 34 |
| C2 | 31 | F/F | 1 | IR | MUD | PB | TBI/Cy/ATG | MTX/CsA | I | None | + (29) | 33 |
| C3 | 33 | F/M | 1 | IR | MUD | PB | TBI/Cy/ATG | MTX/CsA | III | Ext | − (28) | 32 |
| C4 | 44 | M/F | 1 | HR | SIB | BM | Bu/Cy | MTX/CsA | II | Lim | − (24) | 30 |
| C5 | 53 | M/F | 1 | IR | MUD | BM | fTBI/Cy/ATG | MMF/CsA | I | None | + (24) | 25 |
| C6 | 49 | M/M | 1 | LR | MUD | PB | Bu/Cy/ATG | MTX/CsA | III | Ext | − (5) | 7 (D) |
| C7 | 35 | F/M | 1 | LR | MUD | BM | Bu/Cy/ATG | MTX/CsA | II | Lim | − (18) | 22 |
| C8 | 50 | M/F | 1 | LR | SIB | PB | Bu/Cy | MTX/CsA | I | Lim | + (16) | 21 |
| C9 | 44 | F/F | 1 | IR | MUD | BM | Bu/Cy/ATG | MTX/CsA | I | None | + (11) | 19 (R) |
| C10 | 40 | M/M | 1 | IR | MUD | PB | fTBI/Cy/ATG | MTX/CsA | None | None | + (8) | 9 (R) |
| Patient no. . | Age, y . | Sex, recipient/donor . | CP . | HS . | Donor . | BM/PB . | Conditioning . | GVHD prophylaxis . | Acute GVHD . | Chronic GVHD . | MRD status, last follow-up (mo) . | Follow-up, mo (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N1 | 63 | F/F | 1 | IR | SIB | PB | Flu/Bu/ATG | MMF/CsA/Pr | I | None | − (27) | 29 (R) |
| N2 | 50 | M/M | 1 | HR | SIB | PB | Flu/Bu/ATG | MTX/CsA | III | None | − (5) | 5 (D) |
| N3 | 53 | F/F | 1 | NA | SIB | PB | Flu/Bu/ATG | MTX/CsA | I | Lim | − (21) | 22 |
| N4 | 55 | F/F | 1 | IR | MUD | PB | Flu/Bu/ATG | MTX/CsA | None | Lim | − (20) | 21 |
| N5 | 62 | F/M | 1 | IR | SIB | PB | Flu/Bu/ATG | MTX/CsA | None | Lim | − (7) | 8.5 |
| N6 | 56 | F/M | 1 | IR | MUD | BM | Flu/Bu/ATG | MTX/CsA | I | None | + (7) | 8.5 |
| N7 | 56 | F/F | 1 | IR | SIB | BM | Flu/Bu/ATG | MTX/CsA | None | None | − (6) | 6 |
| N8 | 58 | F/F | 1 | HR | SIB | PB | Flu/Bu/ATG | CsA | II | Lim | + (29) | 31 |
| N9 | 40 | F/M | 1 | LR | SIB | PB | Flu/Bu/ATG | CsA | II | Ext | − (24) | 24 |
| N10 | 44 | M/M | 1 | LR | SIB | PB | Flu/Bu/ATG | CsA | II | Lim | − (18) | 21 |
| N11 | 50 | M/M | 1 | LR | SIB | PB | Flu/Bu/ATG | MTX/CsA | II | Lim | − (20) | 20 |
| N12 | 49 | M/M | 1 | HR | MUD | BM | Flu/Bu/ATG | MTX/CsA | II | Ext | + (17) | 17 (D) |
| N13 | 46 | F/M | 1 | LR | MUD | PB | Flu/Bu/ATG | MTX/CsA | I | None | − (13) | 14 |
| N14 | 36 | F/M | 1 | LR | MUD | PB | Flu/Bu/ATG | MTX/CsA | None | None | − (13) | 14 |
| N15 | 51 | M/F | 1 | HR | SIB | PB | Flu/Bu/ATG | MTX/CsA | II | Lim | + (8) | 8 |
| C1 | 35 | M/M | 1 | LR | MUD | BM | TBI/Cy/ATG | MTX/CsA | I | Ext | − (28) | 34 |
| C2 | 31 | F/F | 1 | IR | MUD | PB | TBI/Cy/ATG | MTX/CsA | I | None | + (29) | 33 |
| C3 | 33 | F/M | 1 | IR | MUD | PB | TBI/Cy/ATG | MTX/CsA | III | Ext | − (28) | 32 |
| C4 | 44 | M/F | 1 | HR | SIB | BM | Bu/Cy | MTX/CsA | II | Lim | − (24) | 30 |
| C5 | 53 | M/F | 1 | IR | MUD | BM | fTBI/Cy/ATG | MMF/CsA | I | None | + (24) | 25 |
| C6 | 49 | M/M | 1 | LR | MUD | PB | Bu/Cy/ATG | MTX/CsA | III | Ext | − (5) | 7 (D) |
| C7 | 35 | F/M | 1 | LR | MUD | BM | Bu/Cy/ATG | MTX/CsA | II | Lim | − (18) | 22 |
| C8 | 50 | M/F | 1 | LR | SIB | PB | Bu/Cy | MTX/CsA | I | Lim | + (16) | 21 |
| C9 | 44 | F/F | 1 | IR | MUD | BM | Bu/Cy/ATG | MTX/CsA | I | None | + (11) | 19 (R) |
| C10 | 40 | M/M | 1 | IR | MUD | PB | fTBI/Cy/ATG | MTX/CsA | None | None | + (8) | 9 (R) |
CP indicates chronic phase; HS, Hasford score at diagnosis; BM, bone marrow; PB, peripheral blood stem cells; GVHD, graft-versus-host disease; MRD, minimal residual disease; N1 to N15, patients with nonmyeloablative conditioning; F, female; IR, intermediate risk; SIB, sibling donor; Flu, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; MMF, mycophenolate mofetil; CsA, cyclosporine A; Pr, prednisolone; R, relapse; M, male; HR, high risk; MTX, methotrexate; D, dead; NA, not available; Lim, limited; MUD, matched unrelated donor; LR, low risk; Ext, extensive; C1 to C10, patients with conventional conditioning; TBI, total body irradiation; Cy, cyclophosphamide, and fTBI, fractionated TBI.